<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"><url><loc><![CDATA[https://crisprmedicinenews.com/]]></loc><lastmod>2026-03-25T05:41:56+01:00</lastmod><changefreq>weekly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-live/]]></loc><lastmod>2025-02-13T21:28:24+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/]]></loc><lastmod>2022-04-01T20:23:25+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trials/]]></loc><lastmod>2026-03-25T05:43:21+01:00</lastmod><changefreq>weekly</changefreq><priority>0.5</priority><image:image><image:loc><![CDATA[https://crisprmedicinenews.com/typo3temp/assets/images/csm_CMN_Trials_2023_-3_9025a462f6_1432e9b736.jpg]]></image:loc><image:title><![CDATA[Clinical Trials]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-db-20/]]></loc><lastmod>2026-02-22T10:32:38+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/crisprmed/]]></loc><lastmod>2025-08-16T22:03:22+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority><image:image><image:loc><![CDATA[https://crisprmedicinenews.com/typo3temp/assets/images/csm_CRISPRMED25_Banner_Final-III_1c0c672479_3b70d60bdb.jpg]]></image:loc><image:title><![CDATA[CRISPRMED]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/crisprmed/crisprmed24/]]></loc><lastmod>2025-04-17T11:30:31+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority><image:image><image:loc><![CDATA[https://crisprmedicinenews.com/typo3temp/assets/images/csm_CRISPRMED24_Banner-II_bab3f449f9_95f22a895d.jpg]]></image:loc><image:title><![CDATA[CRISPRMED24]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/crisprmed/crisprmed25/]]></loc><lastmod>2025-06-03T18:36:46+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/crisprmed/crisprmed26/]]></loc><lastmod>2026-03-25T05:42:30+01:00</lastmod><changefreq>weekly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/crisprmed/crisprmed26/wdc-crisprmed26-contest/]]></loc><lastmod>2025-11-04T08:34:25+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/crisprmed/crisprmed26/crisprmed26-conference-kit/]]></loc><lastmod>2026-02-22T18:14:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/crisprmed/crisprmed-global-brazil-2026/]]></loc><lastmod>2025-08-26T08:24:22+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/crisprmed/crisprmed-website-policies/]]></loc><lastmod>2025-08-01T13:56:34+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/egmedc/]]></loc><lastmod>2026-03-15T18:49:45+01:00</lastmod><changefreq>monthly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-intelligence/]]></loc><lastmod>2026-02-22T10:27:40+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/webinars/]]></loc><lastmod>2026-02-04T20:31:04+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/webinars/cmn-webinars-on-demand-all/]]></loc><lastmod>2021-11-09T09:29:44+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority><image:image><image:loc><![CDATA[https://crisprmedicinenews.com/typo3temp/assets/images/csm_CMN_Webinars_Master_Template_-_Teasers_June_Update210617_2___1__fecbd7451d_c1b63e58f1.jpg]]></image:loc><image:title><![CDATA[CMN Webinars On-demand - All]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-disrupting-the-care-of-cardiovascular-disease-with-single-course-gene-editing-medicines/]]></loc><lastmod>2023-08-26T09:53:44+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-taking-the-guesswork-out-of-drug-development-crispr-select-validates-drug-targets-and-drug-responders-early-and-conclusively/]]></loc><lastmod>2023-06-14T09:44:26+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-clinical-grade-grna-for-genomic-medicines-making-sense-of-the-crispr-regulatory-landscape/]]></loc><lastmod>2023-05-29T20:10:19+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-enhancing-t-cell-function-for-cancer-immunotherapy-with-crispr/]]></loc><lastmod>2023-03-20T07:40:19+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-engineering-approaches-to-improve-crispr-technologies/]]></loc><lastmod>2022-10-10T13:15:30+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-development-of-crisprcas9-based-therapies-against-alzheimers-disease/]]></loc><lastmod>2022-11-14T09:10:57+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-epigenomic-editing-ameliorates-detrimental-effects-of-adolescent-alcohol-exposure/]]></loc><lastmod>2022-08-31T17:58:52+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-gene-editing-for-rare-skin-disorder-junctional-epidermolysis-bullosa/]]></loc><lastmod>2022-08-31T18:06:56+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-multiplexed-genome-regulation-in-vivo-with-hyper-efficient-cas12a/]]></loc><lastmod>2022-08-31T17:57:26+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-the-tcr-therapy-revival-engineering-t-cells-with-wt1-specific-receptors-to-fight-hematological-and-solid-malignancies/]]></loc><lastmod>2022-06-19T09:29:39+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-controllable-genome-editing-with-split-engineered-base-editors/]]></loc><lastmod>2022-05-30T09:31:10+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-controllable-genome-editing-with-split-engineered-base-editors/]]></loc><lastmod>2022-04-28T08:23:43+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-crispr-based-control-of-insect-borne-diseases/]]></loc><lastmod>2022-03-31T08:42:59+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-crispr-and-metachromatic-leukodystrophy-mld-kopi-1/]]></loc><lastmod>2022-03-31T08:18:04+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-crispr-off-targets-ii/]]></loc><lastmod>2021-12-28T11:34:35+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/cmn-webinars/cmn-webinar-rare-diseases/]]></loc><lastmod>2021-12-28T11:34:38+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/webinars/cmn-webinar-crispr-onoff-target/]]></loc><lastmod>2021-12-28T11:34:42+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/webinars/cmn-webinar-crispr-off-targets/]]></loc><lastmod>2021-12-28T11:34:44+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/webinars/cmn-webinar-crispr-delivery-systems/]]></loc><lastmod>2021-12-28T11:34:46+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/webinars/cmn-webinar-certainty-after-crispr/]]></loc><lastmod>2021-11-09T09:25:42+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/advertising/]]></loc><lastmod>2026-01-02T08:26:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/wdc/]]></loc><lastmod>2025-08-05T20:07:47+02:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/about/]]></loc><lastmod>2025-12-19T21:35:10+01:00</lastmod><changefreq>yearly</changefreq><priority>0.5</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-27-march-2026-your-weekly-crispr-medicine-news/]]></loc><lastmod>2026-03-27T12:14:53+01:00</lastmod><changefreq>weekly</changefreq><priority>0.8</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_csm_iStock-949472768_f895c2b348_f04b20c3e0_6a4fa29132.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (27 March 2026) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/scribe-therapeutics-positions-epigenetic-crispr-for-durable-ldl-c-reduction/]]></loc><lastmod>2026-03-25T11:03:23+01:00</lastmod><changefreq>weekly</changefreq><priority>0.8</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_OakesLandskab_9569b5dc5d_0ac1772d02.jpg]]></image:loc><image:title><![CDATA[Scribe Therapeutics Positions Epigenetic CRISPR for Durable LDL-C Reduction]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/mmej-targeting-improves-crispr-precision/]]></loc><lastmod>2026-03-23T14:56:35+01:00</lastmod><changefreq>weekly</changefreq><priority>0.8</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief2303_f45afba6d2_92dfd6c59c.jpg]]></image:loc><image:title><![CDATA[MMEJ targeting improves CRISPR precision]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-20-march-2026-your-weekly-crispr-medicine-news/]]></loc><lastmod>2026-03-20T11:37:57+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_20251112__CAR-T_NHL_lymphoma_fe7115b85e_f075b01a3a.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (20 March 2026) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/delivery-of-gene-editing-components-to-skeletal-muscle-using-lipid-nanoparticles-a-game-changer-for/]]></loc><lastmod>2026-03-18T16:32:33+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CeciliaCover_d266e2cbd2_e8d93be8a0.jpg]]></image:loc><image:title><![CDATA[Delivery of Gene Editing Components to Skeletal Muscle Using Lipid Nanoparticles: A Game Changer for Muscle Diseases]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-ready-mosquito-strain-informs-vector-control/]]></loc><lastmod>2026-03-16T15:18:00+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief0316_e6283af335_a32349e0e9.jpg]]></image:loc><image:title><![CDATA[CRISPR-Ready Mosquito Strain Informs Vector Control]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-13-march-2026-your-weekly-crispr-medicine-news/]]></loc><lastmod>2026-03-20T08:38:31+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1303_1737c1f65c_3bddc2ad20.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (13 March 2026) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/install-makes-non-viral-gene-insertion-work-in-vivo/]]></loc><lastmod>2026-03-11T17:07:12+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_KleinstiverTou_61c7041f3a_63ef57813d.jpg]]></image:loc><image:title><![CDATA[INSTALL Makes Non-Viral Gene Insertion Work In Vivo]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/inhaled-crispr-cas9-nanoparticles-disrupt-sting1-in-fibrotic-lungs/]]></loc><lastmod>2026-03-09T14:47:02+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief0903_2b3001b978_a1024eb171.jpg]]></image:loc><image:title><![CDATA[Inhaled CRISPR-Cas9 nanoparticles disrupt Sting1 in fibrotic lungs]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-6-march-2026-your-weekly-crispr-medicine-news/]]></loc><lastmod>2026-03-06T15:36:47+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML0602_3d386036d0_7d4ec9fd23.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (6 March 2026) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/the-progeria-research-foundation-and-forge-biologics-announce-manufacturing-partnership-to-advance-g/]]></loc><lastmod>2026-03-03T20:00:01+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-armed-phages-clear-first-human-safety-bar/]]></loc><lastmod>2026-03-10T12:09:48+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_GoendahlHelm_9add3db4fd_f1aca4b3a6.jpg]]></image:loc><image:title><![CDATA[CRISPR-Armed Phages Clear First Human Safety Bar]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/augusts-case-when-treatment-exists-but-access-does-not/]]></loc><lastmod>2026-03-04T14:16:13+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_August_Photo_2e4ed46620_f53530d4f9.jpg]]></image:loc><image:title><![CDATA[August’s Case: When Treatment Exists but Access Does Not]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-cas12a-enables-portable-detection-of-antibiotic-resistance-genes/]]></loc><lastmod>2026-03-02T10:25:13+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief0203_6eb9d0d9f2_f9d41a2ed3.jpg]]></image:loc><image:title><![CDATA[CRISPR-Cas12a enables portable detection of antibiotic resistance genes]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-27-february-2026-your-weekly-crispr-medicine-news/]]></loc><lastmod>2026-02-27T08:57:32+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML2702_4e4386eaa1_21e6780e3c.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (27 February 2026) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/engineered-virus-like-particles-redefine-crispr-cas-delivery-options/]]></loc><lastmod>2026-02-25T14:09:21+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Special2502_5b4f1056ca_0d9bf72d6b.jpg]]></image:loc><image:title><![CDATA[Engineered Virus-Like Particles Redefine CRISPR-Cas Delivery Options]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/spatial-crispr-maps-gene-effects-in-the-brain/]]></loc><lastmod>2026-02-23T13:12:03+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief2302_58baebdd3e_33029e911c.jpg]]></image:loc><image:title><![CDATA[Spatial CRISPR maps gene effects in the brain]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-20-february-2026-your-weekly-crispr-medicine-news/]]></loc><lastmod>2026-02-20T13:41:46+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML2002_4a67840544_c035d05880.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (20 February 2026) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/cellares-and-university-of-wisconsin-school-of-medicine-and-public-health-expand-partnership-to-clin/]]></loc><lastmod>2026-02-18T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/fda-clears-arcus-editor-for-duchenne-hot-spot/]]></loc><lastmod>2026-02-18T15:00:14+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CTU1802_e004dc1855_b1aa92dea4.jpg]]></image:loc><image:title><![CDATA[FDA Clears ARCUS Editor for Duchenne Hot-spot]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/flashpoint-therapeutics-announces-major-publication-on-novel-hpv-cancer-vaccine/]]></loc><lastmod>2026-02-18T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/seek-labs-awarded-2-million-federal-grant-for-a-novel-crispr-based-mutation-resistant-therapeutic/]]></loc><lastmod>2026-02-17T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/watchmaker-genomics-licenses-crispr-cas9-intellectual-property-from-caribou-biosciences-to-increase/]]></loc><lastmod>2026-02-17T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/scribe-therapeutics-achieves-second-success-milestone-for-in-vivo-program-in-collaboration-with-eli/]]></loc><lastmod>2026-02-17T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-cas-inspired-activator-rescues-dravet-syndrome-mice-1/]]></loc><lastmod>2026-02-26T10:02:42+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief1602_f2a3426dd1_28fc8415b0.jpg]]></image:loc><image:title><![CDATA[CRISPR-Cas-inspired activator rescues Dravet syndrome mice]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-13-february-2026-your-weekly-crispr-medicine-news/]]></loc><lastmod>2026-02-13T13:45:58+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1302_44cbc6c1a7_3a055cf0f1.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (13 February 2026) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/vertex-reports-fourth-quarter-and-full-year-2025-financial-results/]]></loc><lastmod>2026-02-13T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/painting-crispr-onto-the-skin-curing-a-rare-genetic-skin-diseases-with-topical-base-editing/]]></loc><lastmod>2026-02-11T16:34:33+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_GauravSarah_8bd8dddff9_81b3e5eee7.jpg]]></image:loc><image:title><![CDATA[Painting CRISPR onto the Skin: Curing a Rare Genetic Skin Diseases with Topical Base Editing]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-refines-machine-learning-kidney-cancer-drug-targets/]]></loc><lastmod>2026-02-09T16:34:04+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML0902_fcb993d2a3_c934a62225.jpg]]></image:loc><image:title><![CDATA[CRISPR refines machine learning kidney cancer drug targets]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-6-february-2026-your-weekly-crispr-medicine-news/]]></loc><lastmod>2026-02-06T15:14:48+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML0602_2a54175cec_4ae0d00efc.png]]></image:loc><image:title><![CDATA[CMN Weekly (6 February 2026) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/ambrys-contributions-to-maves-support-thousands-of-patient-reclassifications-and-expand-to-new-gene/]]></loc><lastmod>2026-02-04T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/first-patient-dosed-with-crispr-hbv-silencer/]]></loc><lastmod>2026-02-05T07:04:34+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CTU0402_2a6beaa26b_5f15e27059.jpg]]></image:loc><image:title><![CDATA[First patient dosed with CRISPR HBV silencer]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/machine-learning-customises-crispr-cas-pam-recognition/]]></loc><lastmod>2026-02-02T17:29:19+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_20251029__deep_learning_726ac8e73b_39e93be5c6.jpg]]></image:loc><image:title><![CDATA[Machine learning customises CRISPR-Cas PAM recognition]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-30-january-2026-your-weekly-crispr-medicine-news/]]></loc><lastmod>2026-01-30T13:46:18+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_20250505__Skin_a88f592802_a511068ce5.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (30 January 2026) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cellectis-bets-on-non-viral-editing-for-therapy-gains/]]></loc><lastmod>2026-01-28T13:49:26+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ValtonCover_59b526505a_05c4f7c921.jpg]]></image:loc><image:title><![CDATA[Cellectis Bets on Non-Viral Editing for Therapy Gains]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/acute-myeloid-leukaemia-nct05942599/]]></loc><lastmod>2026-02-24T22:46:54+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/hematologic-malignancies-nct04614636/]]></loc><lastmod>2026-02-26T22:36:19+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-screens-map-cancer-vulnerabilities-across-driver-mutations/]]></loc><lastmod>2026-01-26T13:53:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief2601_da4ca66d72_6365177de6.jpg]]></image:loc><image:title><![CDATA[CRISPR screens map cancer vulnerabilities across driver mutations]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-23-january-2026-your-weekly-crispr-medicine-news/]]></loc><lastmod>2026-01-23T13:33:15+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML2301_d7e49bbe59_c9fda4f85a.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (23 January 2026) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/removing-the-brakes-genomic-medicine-in-experimental-clinical-practice/]]></loc><lastmod>2026-01-23T14:48:16+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_OM-2_4469aefa90_a676c07e96.jpg]]></image:loc><image:title><![CDATA[Removing the Brakes – Genomic Medicine in Experimental Clinical Practice]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/corrixr-therapeutics-announces-publication-of-additional-preclinical-data-corroborating-ability-of-n/]]></loc><lastmod>2026-01-23T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/regulators-fast-track-gene-editing-for-neonatal-liver-disease/]]></loc><lastmod>2026-01-21T14:59:44+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Clinical2101_aaefef7d21_a70f7a5cb8.jpg]]></image:loc><image:title><![CDATA[Regulators fast-track gene editing for neonatal liver disease]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/scribe-therapeutics-projected-to-enter-the-clinic-in-mid-2026-with-stx-1150-a-pcsk9-targeting-crisp/]]></loc><lastmod>2026-01-20T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/anti-crispr-protein-reveals-sgrna-vulnerability-in-cas9/]]></loc><lastmod>2026-01-28T14:43:59+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief1901_d08cebdfd0_094082abee.jpg]]></image:loc><image:title><![CDATA[Anti-CRISPR protein reveals sgRNA vulnerability in Cas9]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-16-january-2026-your-weekly-crispr-medicine-news/]]></loc><lastmod>2026-01-28T14:27:36+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1601_b9ef871452_7bcb4ffe84.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (16 January 2026) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/beyond-the-rd-pharma-walls-safari-visit-of-middle-eastern-and-african-researchers/]]></loc><lastmod>2026-01-16T14:39:31+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_GuestPost1601_a5c077efbc_7bd51d7bae.jpg]]></image:loc><image:title><![CDATA[Beyond the R&D Pharma Walls: Safari visit of Middle Eastern and African Researchers]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/flashpoint-therapeutics-appoints-venkat-r-krishnamurthy-phd-as-chief-scientific-officer/]]></loc><lastmod>2026-01-15T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/two-step-crispr-enables-full-length-mouse-gene-humanisation/]]></loc><lastmod>2026-01-14T15:08:30+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Special1401Cover_7a56f4bf17_e33d95c8c0.jpg]]></image:loc><image:title><![CDATA[Two-Step CRISPR Enables Full-Length Mouse Gene Humanisation]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/junevity-announces-first-peer-reviewed-research-showing-single-target-repression-can-reprogram-cellu/]]></loc><lastmod>2026-01-12T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/single-cell-sequencing-maps-crispr-cas9-chromosomal-damage/]]></loc><lastmod>2026-01-12T14:00:13+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief1201_588041a9b6_c5c5ec52e3.jpg]]></image:loc><image:title><![CDATA[Single-Cell Sequencing Maps CRISPR-Cas9 Chromosomal Damage]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/mammoth-biosciences-to-present-at-44th-annual-jp-morgan-healthcare-conference/]]></loc><lastmod>2026-01-09T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/aurora-therapeutics-launches-to-realize-potential-of-personalized-gene-editing-for-millions-of-patie/]]></loc><lastmod>2026-01-09T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-9-january-2026-your-weekly-crispr-medicine-news/]]></loc><lastmod>2026-01-09T13:31:46+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML0901_500405a630_4ccf3e7afb.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (9 January 2026) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/one-genomics-and-cira-foundation-announce-strategic-research-collaboration-to-advance-precision-geno/]]></loc><lastmod>2026-01-08T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/acuitas-therapeutics-expands-collaboration-with-rna-technologies-amp-therapeutics-through-strategi/]]></loc><lastmod>2026-01-08T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/adicet-bio-provides-corporate-update-and-highlights-expected-2026-milestones/]]></loc><lastmod>2026-01-07T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/off-the-shelf-crispr-car-t-tackles-brain-tumours/]]></loc><lastmod>2026-01-07T14:07:50+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Special0701c_06132709f2_82c69caf4c.jpg]]></image:loc><image:title><![CDATA[Off-the-shelf CRISPR CAR-T tackles brain tumours]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/dem-biopharma-announces-poster-presentation-featuring-dem301-at-the-2026-asco-gastrointestinal-cance/]]></loc><lastmod>2026-01-06T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/alloy-therapeutics-appoints-christian-cobaugh-phd-as-ceo-of-alloy-genetic-medicines/]]></loc><lastmod>2026-01-06T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cas3-generates-large-deletions-in-amyloidosis-model/]]></loc><lastmod>2026-01-05T14:43:18+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief0501_b7a722abc9_a35117f382.jpg]]></image:loc><image:title><![CDATA[Cas3 Generates Large Deletions in Amyloidosis Model]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-rewrites-germline-memory-to-test-epigenetic-inheritance/]]></loc><lastmod>2026-01-14T20:25:38+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Special2912Cover_19ff4cf794_56952c24af.jpg]]></image:loc><image:title><![CDATA[CRISPR rewrites germline memory to test epigenetic inheritance]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/modalis-announces-publication-in-human-gene-therapy-of-study-demonstrating-efficient-lama1-gene-acti/]]></loc><lastmod>2025-12-25T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-screen-links-splicing-control-to-therapy/]]></loc><lastmod>2025-12-22T02:04:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Special2212_852b8b77d3_1ca837887c.jpg]]></image:loc><image:title><![CDATA[CRISPR screen links splicing control to therapy]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-19-december-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-12-19T12:01:36+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1912_01d5dd6b8c_fc9c108785.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (19 December 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/nchroma-bio-clears-first-clinical-hurdle-for-crispr-based-epigenetic-hbv-therapy/]]></loc><lastmod>2025-12-17T09:59:43+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CTU1712_03e6c0a508_3c81cb1dca.jpg]]></image:loc><image:title><![CDATA[nChroma Bio clears first clinical hurdle for CRISPR-based epigenetic HBV therapy]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/roslinct-and-ayrmid-ltd-announce-expansion-of-strategic-partnership-to-manufacture-omisirger-omidu/]]></loc><lastmod>2025-12-16T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/scribe-therapeutics-to-present-at-the-44th-annual-jp-morgan-healthcare-conference/]]></loc><lastmod>2025-12-15T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cas5-dimer-structure-offers-clues-for-crispr-system-engineering/]]></loc><lastmod>2025-12-15T13:34:27+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief1512_43a6944872_bd341629f2.jpg]]></image:loc><image:title><![CDATA[Cas5 dimer structure offers clues for CRISPR system engineering]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-12-december-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-12-12T15:17:42+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1212_da159fc3bc_2f05ce6cf1.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (12 December 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/sickle-cell-disease-scd-and-transfusion-dependent-beta-thalassemia-tdt-nct06647979/]]></loc><lastmod>2026-03-04T22:18:34+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/researchers-engineer-programmable-gene-activation-cascades/]]></loc><lastmod>2025-12-21T22:30:55+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Special1210Cover_7b5888eb9e_c915a0469a.jpg]]></image:loc><image:title><![CDATA[Researchers engineer programmable gene activation cascades]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/flashpoint-therapeutics-scientific-founder-chad-a-mirkin-awarded-the-prestigious-harvey-prize/]]></loc><lastmod>2025-12-08T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/new-research-highlights-syntax-bios-platform-for-simple-yet-powerful-programming-of-human-stem-cell/]]></loc><lastmod>2025-12-08T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/vertex-presents-new-data-on-casgevyr-including-first-ever-data-in-children-ages-5-11-years-at-the/]]></loc><lastmod>2025-12-06T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/mice-model-market-trends-and-growth-opportunities-by-segment-amp-region-2025-2032-transformative/]]></loc><lastmod>2025-12-05T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-5-december-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-12-05T16:36:06+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML0512_ff66c39ad5_d6e3cb97ba.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (5 December 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/screening-identifies-improved-cas9-for-precise-editing/]]></loc><lastmod>2025-12-03T13:55:23+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief0312_6503ca4ef4_e6d1b74d78.jpg]]></image:loc><image:title><![CDATA[Screening identifies improved Cas9 for precise editing]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/corrixr-therapeutics-inhatarget-therapeutics-and-merxin-ltd-announce-strategic-collaboration-for-t/]]></loc><lastmod>2025-12-02T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/regeneron-and-tessera-advance-tsra-196-toward-indcta-filings/]]></loc><lastmod>2025-12-01T19:45:51+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CTU0112_af095dc16b_89db299794.jpg]]></image:loc><image:title><![CDATA[Regeneron and Tessera advance TSRA-196 toward IND/CTA filings]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-28-november-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-11-28T14:27:04+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML2811_6c08480d33_6846259111.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (28 November 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/from-promise-to-patients-accelerating-crispr-medicine-in-europe/]]></loc><lastmod>2026-01-23T11:51:39+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_UMC-4_be8f4be68b_0e303cd65f.png]]></image:loc><image:title><![CDATA[From Promise to Patients: Accelerating CRISPR Medicine in Europe]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/breaking-base-editing-rescues-severe-b-thalassaemia-mutations/]]></loc><lastmod>2025-11-26T20:10:10+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Special1126Cover_2a133d5e6b_d3034b010d.jpg]]></image:loc><image:title><![CDATA[Breaking: Base Editing Rescues Severe β-Thalassaemia Mutations]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/fzd6-targeting-reveals-therapeutic-vulnerabilities-in-prostate-cancer/]]></loc><lastmod>2025-11-24T17:44:11+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief2411_4fb8777408_d9364de9d4.jpg]]></image:loc><image:title><![CDATA[FZD6 Targeting Reveals Therapeutic Vulnerabilities in Prostate Cancer]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-21-november-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-11-21T14:07:16+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML2111_3dee69cbb6_8932d1680c.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (21 November 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/cassidy-bio-launches-with-the-goal-to-develop-safer-more-scalable-gene-editing-therapies/]]></loc><lastmod>2025-11-20T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/shape-the-strategic-direction-of-genomic-medicine-at-crisprmed26/]]></loc><lastmod>2025-11-22T08:18:28+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_SPONSORS_1_dc35f75d58_30324cbf51.png]]></image:loc><image:title><![CDATA[Shape the Strategic Direction of Genomic Medicine at CRISPRMED26]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/profluent-raises-106m-to-scale-frontier-ai-models-for-programmable-biology/]]></loc><lastmod>2025-11-19T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/tumour-specific-crispr-restores-chemotherapy-response/]]></loc><lastmod>2025-12-02T07:29:37+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Special1119Cover_c122549e13_8aebfd8693.jpg]]></image:loc><image:title><![CDATA[Tumour-Specific CRISPR Restores Chemotherapy Response]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/yoltech-therapeutics-receives-fda-ind-clearance-to-initiate-global-pivotal-trial-of-in-vivo-gene-edi/]]></loc><lastmod>2025-11-19T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/parse-biosciences-announces-ffpe-compatible-barcoding-technology-for-whole-transcriptome-single-cell/]]></loc><lastmod>2025-11-18T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/acuitas-therapeutics-unveils-next-generation-lipid-nanoparticle-advancements-at-the-2025-mrna-health/]]></loc><lastmod>2025-11-17T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/christianacare-gene-editing-institute-achieves-crispr-breakthrough-that-reverses-chemotherapy-resist/]]></loc><lastmod>2025-11-17T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/corrixr-therapeutics-announces-publication-of-preclinical-data-demonstrating-potential-of-crispr-dir/]]></loc><lastmod>2025-11-17T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/broken-string-biosciences-announces-new-leadership-to-drive-commercialization-of-induce-seqr-platfor/]]></loc><lastmod>2025-11-17T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/scribe-therapeutics-highlights-data-underpinning-its-comprehensive-strategy-targeting-key-lipid-driv/]]></loc><lastmod>2025-11-17T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/neurons-repair-crispr-damage-with-unique-timing/]]></loc><lastmod>2025-11-26T20:36:39+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_20251117__Synapse_40eae48b81_1745e3b4bf.jpg]]></image:loc><image:title><![CDATA[Neurons repair CRISPR damage with unique timing]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/are-you-ready-for-the-crisprmed26-satellite-meetings-in-copenhagen/]]></loc><lastmod>2025-11-17T07:31:20+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_SAT_Meetings_0db56a0c07_8989e0d752.png]]></image:loc><image:title><![CDATA[Are You Ready for the CRISPRMED26 Satellite Meetings in Copenhagen?]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-14-november-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-11-14T15:08:05+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1114Cover_e73a0ae2a5_f98d0b035e.png]]></image:loc><image:title><![CDATA[CMN Weekly (14 November 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/flashpoint-therapeutics-announces-publication-demonstrating-superior-pre-clinical-anti-leukemia-effi/]]></loc><lastmod>2025-11-14T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-pd-1-knockout-allogeneic-car-t-matches-autologous/]]></loc><lastmod>2025-11-12T13:49:26+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CTU1211cover_dffe5cdf8c_f4d8bbcff7.jpg]]></image:loc><image:title><![CDATA[CRISPR PD-1 knockout allogeneic CAR-T matches autologous]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/evox-therapeutics-appoints-douglas-treco-phd-to-board-of-directors/]]></loc><lastmod>2025-11-11T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/adult-participants-treated-with-gene-modified-t-cells-nct06798298/]]></loc><lastmod>2026-03-04T22:18:06+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/immunogen-free-crispr-platform-reveals-metastatic-drivers/]]></loc><lastmod>2025-11-21T09:05:45+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief1011_dc0c19f655_71ac3567bd.jpg]]></image:loc><image:title><![CDATA[Immunogen-free CRISPR platform reveals metastatic drivers]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-7-november-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-11-07T14:24:06+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML0711_4124f35550_6704664e66.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (7 November 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/breaking-deep-learning-multi-dataset-training-improves-crispr-base-editing-predictions/]]></loc><lastmod>2025-11-07T11:06:59+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Special2910_14e94acec6_16f2d0ccb0.jpg]]></image:loc><image:title><![CDATA[Breaking: Deep learning multi-dataset training improves CRISPR base-editing predictions]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/adicet-bio-reports-third-quarter-2025-financial-results-and-provides-business-updates/]]></loc><lastmod>2025-11-06T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/engineered-deaminases-enable-precise-rna-base-editing/]]></loc><lastmod>2025-11-05T11:14:32+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Special0511Cover_add30d0039_d1e8a6ec2c.jpg]]></image:loc><image:title><![CDATA[Engineered deaminases enable precise RNA base editing]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/colossal-biosciences-acquires-viagen-the-leader-in-animal-cloning/]]></loc><lastmod>2025-11-04T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/vertex-reports-third-quarter-2025-financial-results/]]></loc><lastmod>2025-11-04T12:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/start-ups-reignite-debate-over-crispr-embryo-editing/]]></loc><lastmod>2025-11-04T11:38:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief0311_e1d6985153_08af7dfb55.jpg]]></image:loc><image:title><![CDATA[Start-ups reignite debate over CRISPR embryo editing]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-31-october-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-10-31T14:16:19+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML3110_7eef573c8e_07b43a367f.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (31 October 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/highlight-self-limiting-gene-drive-suppresses-malaria-mosquitoes/]]></loc><lastmod>2025-10-29T13:19:13+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Special1029Cover_7c488d0745_e33b28852f.jpg]]></image:loc><image:title><![CDATA[Highlight: Self-limiting gene drive suppresses malaria mosquitoes]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/locus-biosciences-enters-research-collaboration-to-develop-precision-antibacterial-therapies-for-oph/]]></loc><lastmod>2025-10-28T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-screen-identifies-microrna-483-3p-as-a-survival-regulator/]]></loc><lastmod>2025-10-31T12:49:27+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief2710_79558e93b3_87d356e867.jpg]]></image:loc><image:title><![CDATA[CRISPR screen identifies microRNA-483-3p as a survival regulator]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crisprmed26-keynote-speaker-announcement-meet-dr-michel-sadelain/]]></loc><lastmod>2025-10-29T22:20:12+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_MSAD-III_00bc0cf0fc_e192f548e5.jpg]]></image:loc><image:title><![CDATA[CRISPRMED26 Keynote Speaker Announcement: Meet Dr. Michel Sadelain]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-24-october-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-10-24T11:06:11+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-502836820_1f768fce45_8a835e0c3f.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (24 October 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/dna-cancer-vaccine-clinical-trials-report-2026-development-technology-platforms-amp-market-oppor/]]></loc><lastmod>2025-10-22T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-epigenetic-editing-delivers-durable-multiplexed-gene-silencing-in-t-cells/]]></loc><lastmod>2025-10-30T07:06:24+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CoverSpecial2210_5f658f8038_205577f6d2.jpg]]></image:loc><image:title><![CDATA[CRISPR Epigenetic Editing Delivers Durable Multiplexed Gene Silencing in T Cells]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-screen-identifies-sox2-as-key-glioblastoma-regulator/]]></loc><lastmod>2025-10-20T17:10:37+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief2010_5f2729409e_a23c1e76a6.jpg]]></image:loc><image:title><![CDATA[CRISPR Screen Identifies SOX2 as Key Glioblastoma Regulator]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-17-october-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-10-17T14:21:25+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1710_2c25e7f17f_04354850d5.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (17 October 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/syntase-gene-editor-corrects-antitrypsin-deficiency-in-vivo/]]></loc><lastmod>2025-10-15T10:26:40+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CTU1510_808f9b4386_cd51f9f6ed.jpg]]></image:loc><image:title><![CDATA[SyNTase Gene Editor Corrects Antitrypsin Deficiency In Vivo]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/new-paper-out-today-dial-system-fine-tunes-gene-expression-levels/]]></loc><lastmod>2025-10-13T14:52:03+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief1310_1e8b8d04ae_58198d2b04.jpg]]></image:loc><image:title><![CDATA[New paper out today: DIAL system fine-tunes gene expression levels]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/trieste-laquila-rome-the-italian-genomics-triangle-assembles-the-new-diploid-rpe-1-genome-the-m/]]></loc><lastmod>2025-10-10T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-10-october-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-10-10T14:39:45+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1010_dc957fe598_a804d564ca.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (10 October 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/parse-biosciences-invalidates-scale-biosciences-now-10x-genomics-patent/]]></loc><lastmod>2025-10-09T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/atrandi-biosciences-to-showcase-latest-single-cell-multiomics-advancements-at-the-american-society-o/]]></loc><lastmod>2025-10-08T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/tempus-joins-parse-biosciences-certified-service-provider-network/]]></loc><lastmod>2025-10-08T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/vectorbuilder-redefines-plasmid-standards-with-minivec/]]></loc><lastmod>2025-10-08T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/highlight-crispr-gene-editing-exposes-hidden-switch-in-inflammatory-receptor/]]></loc><lastmod>2025-10-08T14:04:22+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Special0810Cover_5225c4137e_659e515c7c.jpg]]></image:loc><image:title><![CDATA[Highlight: CRISPR Gene Editing Exposes Hidden Switch in Inflammatory Receptor]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/algen-biotechnologies-announces-multi-target-partnership-to-advance-ai-powered-drug-discovery-in-imm/]]></loc><lastmod>2025-10-06T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/protein-engineering-for-pharmaceutical-biotechnology-training-course-enhance-your-knowledge-in-pro/]]></loc><lastmod>2025-10-06T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-screens-decode-dual-regulatory-logic-at-the-xist-locus/]]></loc><lastmod>2025-10-22T03:10:33+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief0610_0d0adec1ad_b3ae07ca96.jpg]]></image:loc><image:title><![CDATA[CRISPR screens decode dual regulatory logic at the Xist locus]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/from-blurry-to-4k-dna-dante-omics-ai-rockefeller-university-giunta-lab-and-global-partners-assemb/]]></loc><lastmod>2025-10-03T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-3-october-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-10-06T09:26:58+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML0310_e7a8e222b4_f3d9392774.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (3 October 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/australias-largest-university-establishes-monash-boston-hub-to-accelerate-global-biotech-partners/]]></loc><lastmod>2025-10-02T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/colossal-celebrates-the-first-birthday-of-romulus-amp-remus/]]></loc><lastmod>2025-10-01T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/mammoth-biosciences-to-present-preclinical-data-on-mb-111-at-the-european-society-of-gene-amp-cell/]]></loc><lastmod>2025-10-01T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/base-editing-rescues-liver-disease-in-organoids/]]></loc><lastmod>2025-10-01T11:53:33+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief0110Cover_8651d549c0_46d27b8441.jpg]]></image:loc><image:title><![CDATA[Base editing rescues liver disease in organoids]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/parse-biosciences-expands-global-access-by-certifying-single-cell-discoveries-as-a-service-provider/]]></loc><lastmod>2025-09-30T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/interview-multiplex-base-editing-safely-enhances-sickle-therapy/]]></loc><lastmod>2025-09-29T13:27:27+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Special2909Cover_40ad71e937_ddda7652e1.jpg]]></image:loc><image:title><![CDATA[Interview: Multiplex Base Editing Safely Enhances Sickle Therapy]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-26-september-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-09-26T13:13:26+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML2609_98c3b602ad_8c7c22f89d.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (26 September 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/integrated-dna-technologies-launches-new-enhancer-protein-to-accelerate-crispr-based-therapies-from/]]></loc><lastmod>2025-09-25T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/seek-labs-selected-as-participant-of-arpa-h-investor-catalyst-hub-spoke-network-and-rapid-response-p/]]></loc><lastmod>2025-09-24T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/united-states-next-generation-sequencing-ngs-market-research-2025-2033-personalized-medicine-res/]]></loc><lastmod>2025-09-24T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/highlight-microscopic-beads-supercharge-crispr-virus-detection/]]></loc><lastmod>2025-09-24T16:00:29+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Special2409cover_7c98ad8962_e5769a3e5e.jpg]]></image:loc><image:title><![CDATA[Highlight: Microscopic Beads Supercharge CRISPR Virus Detection]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/colorectal-cancer-crc-nct07035002/]]></loc><lastmod>2026-02-25T10:45:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/alpha1-antitrypsin-deficiency-aatd-nct06892236/]]></loc><lastmod>2026-02-15T22:38:18+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/non-small-cell-lung-cancer-nsclc-nct06097962/]]></loc><lastmod>2025-09-22T23:18:34+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/non-small-cell-lung-cancer-nsclc-nct06097962-2/]]></loc><lastmod>2026-02-16T12:30:53+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/in-situ-sequencing-maps-in-vivo-editing/]]></loc><lastmod>2025-09-22T10:28:39+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief2209_0f73ffd9b6_82b5c46d7e.jpg]]></image:loc><image:title><![CDATA[In situ sequencing maps in vivo editing]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/gastric-cancer-and-colorectal-cancer-crc-nct07166263/]]></loc><lastmod>2025-09-22T23:15:58+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/gastric-cancer-and-colorectal-cancer-crc-nct07166263-1/]]></loc><lastmod>2026-02-16T13:11:48+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/relapsed-or-refractory-acute-myeloid-leukemia-aml-nct06541444/]]></loc><lastmod>2025-09-22T23:13:40+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/relapsed-or-refractory-acute-myeloid-leukemia-aml-nct06541444-1/]]></loc><lastmod>2026-02-16T12:55:58+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/pediatric-relapsed-or-refractory-acute-myeloid-leukemia-aml-nct06541405/]]></loc><lastmod>2025-09-22T23:07:36+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/pediatric-relapsed-or-refractory-acute-myeloid-leukemia-aml-nct06541405-1/]]></loc><lastmod>2026-02-16T12:56:16+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/soft-tissue-sarcoma-nct06117878/]]></loc><lastmod>2025-09-22T23:05:22+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/soft-tissue-sarcoma-nct06117878-1/]]></loc><lastmod>2026-02-16T12:58:18+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/gastric-cancer-nct06098898/]]></loc><lastmod>2025-09-22T23:02:30+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/gastric-cancer-nct06098898-1/]]></loc><lastmod>2026-02-16T13:00:21+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/refractory-systemic-lupus-erythematosus-sle-nct07083349/]]></loc><lastmod>2025-09-22T22:52:28+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/refractory-systemic-lupus-erythematosus-sle-nct07083349-1/]]></loc><lastmod>2026-02-16T13:04:38+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/beta-thalassemia-nct06717932/]]></loc><lastmod>2025-09-20T22:12:17+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/beta-thalassemia-nct06717932-1/]]></loc><lastmod>2026-03-04T21:57:18+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-19-september-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-09-19T13:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1909_8cd4975b76_644560063c.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (19 September 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/beta-thalassemia-nct06685536/]]></loc><lastmod>2025-09-20T22:12:07+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/beta-thalassemia-nct06685536-1/]]></loc><lastmod>2026-03-04T21:56:13+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/vertex-announces-casgevyr-reimbursement-agreement-for-the-treatment-of-transfusion-dependent-beta-th/]]></loc><lastmod>2025-09-18T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/familial-chylomicronemia-syndrome-fcs-nct07176923/]]></loc><lastmod>2025-09-20T22:11:52+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/familial-chylomicronemia-syndrome-fcs-nct07176923-1/]]></loc><lastmod>2026-02-15T22:34:34+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/merosin-deficient-congenital-muscle-dystrophy-type-1a-mdc1a-nct06582537/]]></loc><lastmod>2025-09-20T22:11:56+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/merosin-deficient-congenital-muscle-dystrophy-type-1a-mdc1a-nct06582537-1/]]></loc><lastmod>2026-03-04T21:54:48+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/ovarian-cancer-oc-nct06846424/]]></loc><lastmod>2025-09-18T12:29:05+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/ovarian-cancer-oc-nct06846424-1/]]></loc><lastmod>2026-02-26T12:26:23+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/arcus-gene-editor-shows-promise-against-hepatitis-b/]]></loc><lastmod>2025-09-17T13:30:39+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CTU1709_44b5960643_789351c6d7.jpg]]></image:loc><image:title><![CDATA[ARCUS Gene Editor Shows Promise Against Hepatitis B]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/malaria-infection-nct06881732/]]></loc><lastmod>2025-09-20T22:12:35+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/malaria-infection-nct06881732-1/]]></loc><lastmod>2026-02-15T22:32:31+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/pencil-biosciences-appoints-jonathan-thon-phd-as-chair-of-the-board-of-directors/]]></loc><lastmod>2025-09-15T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-exposes-ageing-and-mitotic-stress-in-gata2-deficiency/]]></loc><lastmod>2025-09-15T14:29:39+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief1509a_0ac6747112_c383db43ca.jpg]]></image:loc><image:title><![CDATA[CRISPR exposes ageing and mitotic stress in GATA2 deficiency]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/liver-transplant-nct07053488/]]></loc><lastmod>2025-09-18T12:52:36+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/liver-transplant-nct07053488-1/]]></loc><lastmod>2026-02-15T22:31:21+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/high-grade-squamous-intraepithelial-lesions-hsil-nct07170254/]]></loc><lastmod>2025-09-18T12:47:27+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/high-grade-squamous-intraepithelial-lesions-hsil-nct07170254-1/]]></loc><lastmod>2026-02-15T22:30:13+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-12-september-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-09-12T12:20:03+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1209_851050de6a_bd9c155f03.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (12 September 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/egenesis-receives-fda-clearance-for-gene-edited-pig-kidney-trial-in-end-stage-kidney-disease-patient/]]></loc><lastmod>2025-09-17T12:43:55+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-2159471852_c2b883090c_d49dfa7881.jpg]]></image:loc><image:title><![CDATA[eGenesis Receives FDA Clearance for Gene-Edited Pig Kidney Trial in End-Stage Kidney Disease Patients]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/seek-labs-maps-foot-and-mouth-disease-with-bioseekertm-to-advance-development-of-a-pan-target-progra/]]></loc><lastmod>2025-09-09T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/scribe-therapeutics-highlights-latest-data-on-lpa-lowering-therapy-and-novel-ai-platform-for-next/]]></loc><lastmod>2025-09-09T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/vedabio-expands-crispr-based-molecular-detection-platform-with-mammoth-biosciences-technology/]]></loc><lastmod>2025-09-09T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/tiger-reporter-mouse-facilitates-evaluation-of-genome-editing-delivery-methods/]]></loc><lastmod>2025-09-08T15:26:23+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-949472768_6b44909120_5579bc804d.jpg]]></image:loc><image:title><![CDATA[TIGER Reporter Mouse Facilitates Evaluation of Genome-Editing Delivery Methods]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-5-september-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-09-05T17:30:38+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-2182528969_ee0a325a59_44a69e9d83.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (5 September 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/flashpoint-therapeutics-announces-major-publication-supporting-application-of-its-proprietary-struct/]]></loc><lastmod>2025-09-04T12:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/highlight-hificas9-selectively-disables-mutant-kras-in-lung-tumours/]]></loc><lastmod>2025-09-15T21:32:23+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_KRAScover_660ac1adc8_872cddc4f3.jpg]]></image:loc><image:title><![CDATA[Highlight: HiFiCas9 Selectively Disables Mutant KRAS in Lung Tumours]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/enlaza-therapeutics-announces-strategic-collaboration-with-vertex-pharmaceuticals-to-develop-war-loc/]]></loc><lastmod>2025-09-02T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-29-august-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-08-29T17:32:59+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML2908_293c645bd4_1850cb90de.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (29 August 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/axelyf-advances-potent-rna-delivery-platform/]]></loc><lastmod>2025-08-27T12:49:49+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CTU2708cover_5bfe619f62_78353a7e95.jpg]]></image:loc><image:title><![CDATA[Axelyf advances potent RNA delivery platform]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/scribe-therapeutics-to-demonstrate-scientific-and-corporate-leadership-at-upcoming-conferences/]]></loc><lastmod>2025-08-25T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-22-august-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-08-22T14:43:00+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML2208_db2b731528_501ec0dc5f.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (22 August 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/world-leading-developmental-biologist-andrew-pask-phd-joins-colossal-full-time-as-chief-biology-of/]]></loc><lastmod>2025-08-21T12:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/corrixr-therapeutics-secures-1m-investment-from-state-of-delaware/]]></loc><lastmod>2025-08-19T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/prime-editing-corrects-g6pd-deficiency-in-stem-cells/]]></loc><lastmod>2025-09-15T21:33:32+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brtief1908_26d1701da5_0b3431d571.jpg]]></image:loc><image:title><![CDATA[Prime editing corrects G6PD deficiency in stem cells]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/gene-editing-market-size-share-growth-and-forecasts-2021-2024-amp-2025-2033-focus-on-crispr-c/]]></loc><lastmod>2025-08-15T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-15-august-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-08-15T14:59:16+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-2206663268_0f430fab7e_0edd4e39cc.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (15 August 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/recent-clinical-trial-updates-from-crispr-medicine-news/]]></loc><lastmod>2025-09-10T11:11:40+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1216812369_c39011b19c_8f1fd85488.jpg]]></image:loc><image:title><![CDATA[Recent Clinical Trial Updates from CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/type-1-diabetes-t1d-nct06239636/]]></loc><lastmod>2025-09-02T09:45:53+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/type-1-diabetes-t1d-nct06239636-2/]]></loc><lastmod>2026-02-26T18:48:21+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-8-august-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-08-08T12:29:21+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1510897014_5a5147b116_8f038f3eae.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (8 August 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/promega-aobious-resolve-patent-infringement-lawsuit/]]></loc><lastmod>2025-08-05T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/broken-string-biosciences-renews-commitment-to-nist-genome-editing-consortium-bolstering-efforts-to/]]></loc><lastmod>2025-08-05T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/new-partnership-announcement-cmn-x-edugene/]]></loc><lastmod>2025-08-06T10:43:35+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Announcement_EDUGENE-2_f813e21250_53aa2a12ef.png]]></image:loc><image:title><![CDATA[New Partnership Announcement: CMN x EDUGENE]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-edited-beta-cells-avoid-immune-rejection-without-immunosuppressants-in-human-transplantation/]]></loc><lastmod>2025-08-05T15:15:58+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1675614555_5787ce35c2_309d4cf8d8.jpg]]></image:loc><image:title><![CDATA[CRISPR-Edited Beta Cells Avoid Immune Rejection Without Immunosuppressants in Human Transplantation]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/vertex-reports-second-quarter-2025-financial-results/]]></loc><lastmod>2025-08-05T12:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-1-august-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-07-31T19:28:36+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML0108_4cce62eae5_cbbae000e6.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (1 August 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/type-1-primary-hyperoxaluria-ph1-nct06892301/]]></loc><lastmod>2025-08-05T14:04:15+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/type-1-primary-hyperoxaluria-ph1-nct06892301-2/]]></loc><lastmod>2026-02-15T22:27:03+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/profluent-announces-publication-of-generative-ai-research-in-nature-with-new-results-for-opencrispr/]]></loc><lastmod>2025-07-30T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/yolt-203-awarded-ema-orphan-drug-designation-for-treatment-of-primary-hyperoxaluria-type-1/]]></loc><lastmod>2025-08-29T10:52:43+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1360864678_6fc64007f6_9f15d92a7f.jpg]]></image:loc><image:title><![CDATA[YOLT-203 Awarded EMA Orphan Drug Designation for Treatment of Primary Hyperoxaluria Type 1]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/aldevron-launches-new-innovation-center-in-waltham-ma/]]></loc><lastmod>2025-07-30T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/end-stage-renal-disease-nct07053462/]]></loc><lastmod>2025-08-05T14:04:26+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/end-stage-renal-disease-nct07053462-2/]]></loc><lastmod>2026-02-15T22:24:16+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-25-july-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-07-28T09:49:49+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML2507_0a2e32fcb7_baafb9a429.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (25 July 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/relapsed-or-refractory-acute-myeloid-leukaemia-aml-nct07026942/]]></loc><lastmod>2025-08-05T14:04:38+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/relapsed-or-refractory-acute-myeloid-leukaemia-aml-nct07026942-2/]]></loc><lastmod>2026-02-26T18:38:32+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/ovarian-cancer-oc-nct07067255/]]></loc><lastmod>2025-08-05T14:04:49+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/ovarian-cancer-oc-nct07067255-2/]]></loc><lastmod>2026-02-15T22:22:56+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/seek-labs-announces-inclusion-of-veterinary-diseases-in-global-disease-atlas-accelerating-developme/]]></loc><lastmod>2025-07-22T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/extended-crispr-does-not-drive-resistance-in-hiv-rebound/]]></loc><lastmod>2025-07-22T11:35:22+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CoverSpecial0722_c9a2956bcc_436f25d4f1.jpg]]></image:loc><image:title><![CDATA[Extended: CRISPR does not drive resistance in HIV rebound]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-18-july-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-07-20T07:30:13+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1807_b61baed358_b2846ad514.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (18 July 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/integrated-dna-technologies-announces-translational-crispr-portfolio-expansion-with-product-innovati/]]></loc><lastmod>2025-07-16T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/clinical-update-yoltechs-base-editing-therapy-yolt-101-gains-chinese-ind-approval/]]></loc><lastmod>2025-07-20T07:31:09+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1359314170_4b9419218e_4891e55c1b.jpg]]></image:loc><image:title><![CDATA[Clinical Update: YolTech's Base-Editing Therapy YOLT-101 Gains Chinese IND Approval]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-11-july-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-07-11T14:19:24+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1107_7d5fc0b414_c2a9f1e277.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (11 July 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/broken-string-biosciences-and-biolizard-to-develop-ai-for-faster-safer-gene-editing/]]></loc><lastmod>2025-07-10T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/the-ngai-tahu-research-centre-has-entered-into-a-strategic-partnership-with-de-extinction-company-c/]]></loc><lastmod>2025-07-08T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/seek-labs-bioseekertm-powers-development-of-a-first-of-its-kind-programmable-therapeutic-for-respira/]]></loc><lastmod>2025-07-08T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-editors-gain-precision-via-evolved-hotspots/]]></loc><lastmod>2025-07-08T10:13:09+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief0807_75dd449764_463e5660fd.jpg]]></image:loc><image:title><![CDATA[CRISPR editors gain precision via evolved hotspots]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-4-july-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-07-08T10:23:27+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-878306772_fe7e757d1a_8b1e229876.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (4 July 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/breaking-crispr-screen-identifies-endosomal-trafficking-modulators/]]></loc><lastmod>2025-08-27T12:54:26+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Extended3006Cover_8019800e07_c6c183b685.jpg]]></image:loc><image:title><![CDATA[Breaking: CRISPR screen identifies endosomal trafficking modulators]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/gene-and-cell-therapies-targeting-cns-disorders-market-research-2025-2035-novartis-brainstorm-cel/]]></loc><lastmod>2025-06-27T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-27-june-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-06-29T22:01:45+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML2706_1ca605676f_c218d1d153.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (27 June 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/advanced-primary-or-secondary-peritoneal-tumors-nct07004647/]]></loc><lastmod>2025-08-05T14:05:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/advanced-primary-or-secondary-peritoneal-tumors-nct07004647-2/]]></loc><lastmod>2026-02-17T22:13:18+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/recurrent-or-progressive-high-grade-glioma-nct06737146/]]></loc><lastmod>2025-06-26T22:51:47+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/recurrent-or-progressive-high-grade-glioma-nct06737146-2/]]></loc><lastmod>2026-02-17T22:12:18+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/advanced-peritoneal-malignancies-or-abdominal-metastatic-solid-tumors-nct06912152/]]></loc><lastmod>2025-06-26T22:38:35+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/advanced-peritoneal-malignancies-or-abdominal-metastatic-solid-tumors-nct06912152-2/]]></loc><lastmod>2026-02-17T22:12:55+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/transfusion-dependent-beta-thalassemia-nct06479616/]]></loc><lastmod>2025-07-23T17:16:55+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/transfusion-dependent-beta-thalassemia-nct06479616-2/]]></loc><lastmod>2026-03-04T21:53:15+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/relapsed-or-refractory-b-cell-non-hodgkins-lymphoma-nct06838832/]]></loc><lastmod>2025-06-26T19:43:00+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/relapsed-or-refractory-b-cell-non-hodgkins-lymphoma-nct06838832-2/]]></loc><lastmod>2026-02-15T22:11:42+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/retinitis-pigmentosa-nct06952842/]]></loc><lastmod>2025-06-26T19:27:45+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/retinitis-pigmentosa-nct06952842-2/]]></loc><lastmod>2026-02-26T22:02:12+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/snijders-blok-campeau-syndrome-nct06860672/]]></loc><lastmod>2025-06-26T19:16:13+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/snijders-blok-campeau-syndrome-nct06860672-2/]]></loc><lastmod>2026-02-15T22:08:50+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/sickle-cell-disease-nct07000318/]]></loc><lastmod>2025-06-26T17:57:45+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/sickle-cell-disease-nct07000318-3/]]></loc><lastmod>2026-02-15T22:07:14+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/tamoxifen-controls-gene-activation-with-crisprai/]]></loc><lastmod>2025-06-26T15:41:20+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief0626_8733c3795b_ea4b2d0615.jpg]]></image:loc><image:title><![CDATA[Tamoxifen controls gene activation with CRISPRa/i]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/gene-editing-collaboration-rampd-and-licensing-agreements-analysis-report-2025-gain-unprecedent/]]></loc><lastmod>2025-06-24T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/recurrent-or-progressive-glioblastoma-or-grade-3-or-4-idh-mutant-astrocytoma-nct06815029/]]></loc><lastmod>2025-06-24T17:28:47+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/recurrent-or-progressive-glioblastoma-or-grade-3-or-4-idh-mutant-astrocytoma-nct06815029-2/]]></loc><lastmod>2026-02-15T21:44:55+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/silent-mutations-alter-cell-fitness-in-humans-pe-screens-reveal/]]></loc><lastmod>2025-06-24T12:15:47+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief2406_12695c0a61_1481a388f6.jpg]]></image:loc><image:title><![CDATA[Silent mutations alter cell fitness in humans, PE screens reveal]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/seek-labs-maps-measles-virus-with-bioseekertm-opening-the-door-to-first-ever-programmable-antiviral/]]></loc><lastmod>2025-06-24T12:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/phenylketonuria-pku-nct04768348/]]></loc><lastmod>2025-06-23T18:27:19+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/phenylketonuria-pku-nct04768348-2/]]></loc><lastmod>2026-03-04T21:51:40+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/mucopolysaccharidosis-ii-mps-ii-nct05238324/]]></loc><lastmod>2025-06-23T18:18:32+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/long-term-follow-up-study-of-participants-in-any-iecure-protocol-using-an-investigational-product/]]></loc><lastmod>2025-07-23T17:16:07+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/long-term-follow-up-study-of-participants-in-any-iecure-protocol-using-an-investigational-product-2/]]></loc><lastmod>2026-03-04T21:50:55+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/abca4-retinopathy-nct06445322/]]></loc><lastmod>2025-06-23T14:07:37+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/abca4-retinopathy-nct06445322-2/]]></loc><lastmod>2026-03-04T21:49:54+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/x-linked-severe-combined-immunodeficiency-nct06851767/]]></loc><lastmod>2025-06-23T13:56:58+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/x-linked-severe-combined-immunodeficiency-nct06851767-2/]]></loc><lastmod>2026-02-15T21:35:33+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/cd40l-hyperigm-syndrome-nct06959771/]]></loc><lastmod>2025-06-23T13:58:00+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/cd40l-hyperigm-syndrome-nct06959771-2/]]></loc><lastmod>2026-02-15T21:32:54+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/t-cell-acute-lymphoblastic-leukemia-and-lymphoblastic-lymphoma-nct06514794/]]></loc><lastmod>2025-06-23T13:21:26+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/t-cell-acute-lymphoblastic-leukemia-and-lymphoblastic-lymphoma-nct06514794-2/]]></loc><lastmod>2026-03-04T14:50:43+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/relapsed-or-refractory-t-cell-acute-lymphoblastic-leukaemia-t-all-nct05509855-2/]]></loc><lastmod>2026-03-04T21:59:59+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/relapsed-or-refractory-t-cell-acute-lymphoblastic-leukaemia-t-all-nct05509855/]]></loc><lastmod>2025-07-23T17:15:26+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/pleural-malignant-tumors-nct06726564-2/]]></loc><lastmod>2026-02-17T22:16:45+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/pleural-malignant-tumors-nct06726564/]]></loc><lastmod>2025-06-21T18:31:23+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/brain-meninges-and-spinal-cord-metastatic-solid-tumors-nct06742593-2/]]></loc><lastmod>2026-02-17T22:29:08+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/brain-meninges-and-spinal-cord-metastatic-solid-tumors-nct06742593/]]></loc><lastmod>2025-06-21T18:29:10+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-20-june-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-06-20T11:58:57+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-164861799_ddebb93cbb_7aff098ae2.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (20 June 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/intellia-reports-positive-three-year-follow-up-data-from-phase-1-crispr-trial-in-hereditary-angioede/]]></loc><lastmod>2025-06-18T11:58:16+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_20211012_ecb51d3629_c184e207a7.jpg]]></image:loc><image:title><![CDATA[Intellia Reports Positive Three-Year Follow-up Data from Phase 1 CRISPR Trial in Hereditary Angioedema]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/quantum-si-customer-to-showcase-protein-barcoding-for-nucleic-acid-lnp-therapeutic-development-at-fe/]]></loc><lastmod>2025-06-17T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/eli-lilly-to-acquire-verve-therapeutics-to-advance-one-time-cardiovascular-treatments/]]></loc><lastmod>2025-07-20T07:29:24+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1404145480_07b292f357_51981e9d65.jpg]]></image:loc><image:title><![CDATA[Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/hydrogel-enhances-crispr-mediated-tumour-targeting/]]></loc><lastmod>2025-06-16T12:37:07+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Cover1606_18929bcc7a_ed36aa8949.jpg]]></image:loc><image:title><![CDATA[Hydrogel enhances CRISPR-mediated tumour targeting]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/multiple-sclerosis-nct07008378-2/]]></loc><lastmod>2026-02-17T22:38:09+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/multiple-sclerosis-nct07008378/]]></loc><lastmod>2025-06-15T23:48:17+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/hemophilia-b-nct06611436-2/]]></loc><lastmod>2026-02-15T23:56:17+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/hemophilia-b-nct06611436/]]></loc><lastmod>2025-09-24T10:46:31+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/heterozygous-familial-hypercholesterolemia-chictr2400093099-2/]]></loc><lastmod>2026-02-15T23:53:06+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/heterozygous-familial-hypercholesterolemia-chictr2400093099/]]></loc><lastmod>2025-07-22T17:06:48+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/relapsed-or-refractory-b-cell-hematological-malignancies-nct05381181-2/]]></loc><lastmod>2026-02-15T23:51:17+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/relapsed-or-refractory-b-cell-hematological-malignancies-nct05381181/]]></loc><lastmod>2025-06-15T21:06:53+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/castration-resistant-prostate-cancer-nct06895811-2/]]></loc><lastmod>2026-02-16T12:03:54+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/castration-resistant-prostate-cancer-nct06895811/]]></loc><lastmod>2025-06-15T19:57:48+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-13-june-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-06-13T14:08:27+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1306_ba234f3376_29346f80e3.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (13 June 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/refractory-autoimmune-disease-nct06925542/]]></loc><lastmod>2025-06-12T14:19:59+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/refractory-autoimmune-disease-nct06925542-2/]]></loc><lastmod>2026-02-15T23:49:54+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/primary-hyperoxaluria-type-1-nct06839235/]]></loc><lastmod>2025-08-25T12:17:57+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/primary-hyperoxaluria-type-1-nct06839235-2/]]></loc><lastmod>2026-02-15T23:48:51+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/hematologic-and-solid-malignancies-nct06925685/]]></loc><lastmod>2025-07-23T17:13:44+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/hematologic-and-solid-malignancies-nct06925685-2/]]></loc><lastmod>2026-03-04T21:59:18+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/first-cancer-patient-dosed-in-crispr-armed-phage-therapy/]]></loc><lastmod>2025-06-12T10:16:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Skaermbillede_1_43d2e14664_e867e975b4.jpg]]></image:loc><image:title><![CDATA[First cancer patient dosed in CRISPR-armed phage therapy]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/relapsedrefractory-t-cell-acute-lymphoblastic-leukemia-or-lymphoma-nct06934382/]]></loc><lastmod>2025-06-15T23:47:16+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/relapsedrefractory-t-cell-acute-lymphoblastic-leukemia-or-lymphoma-nct06934382-2/]]></loc><lastmod>2026-03-02T23:05:46+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/refractory-pain-due-to-small-fiber-neuropathy-isfn-nct06980948/]]></loc><lastmod>2025-06-23T14:12:50+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/refractory-pain-due-to-small-fiber-neuropathy-isfn-nct06980948-2/]]></loc><lastmod>2026-02-26T12:23:57+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/capsida-receives-fda-ind-clearance-for-its-iv-administered-gene-therapy-for-parkinsons-disease-asso/]]></loc><lastmod>2025-06-11T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/e-coli-infections-nct06938867/]]></loc><lastmod>2025-06-23T14:38:35+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/e-coli-infections-nct06938867-2/]]></loc><lastmod>2026-02-15T23:46:22+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/facioscapulohumeral-muscular-dystrophy-nct06907875/]]></loc><lastmod>2025-08-07T15:15:15+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/facioscapulohumeral-muscular-dystrophy-nct06907875-2/]]></loc><lastmod>2026-02-15T23:44:18+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/familial-hypercholesterolemia-nct06458010/]]></loc><lastmod>2025-06-23T14:31:11+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/familial-hypercholesterolemia-nct06458010-2/]]></loc><lastmod>2026-02-15T23:42:36+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/chronic-granulomatous-disease-nct06559176/]]></loc><lastmod>2025-06-23T14:25:45+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/chronic-granulomatous-disease-nct06559176-2/]]></loc><lastmod>2026-02-15T23:39:25+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/seek-labs-unveils-bioseekertm/]]></loc><lastmod>2025-06-10T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/deep-learning-predicts-crispr-off-target-effects/]]></loc><lastmod>2025-06-10T14:56:32+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief__1006_0c1aa2996f_4fd5085b5e.jpg]]></image:loc><image:title><![CDATA[Deep learning predicts CRISPR off-target effects]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/taconic-biosciences-enters-into-an-exclusive-license-agreement-with-helmholtz-munich-to-expand-its-c/]]></loc><lastmod>2025-06-09T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/modalis-partners-with-solve-fshd-to-develop-crispr-therapy-for-facioscapulohumeral-muscular-dystroph/]]></loc><lastmod>2025-06-09T13:46:20+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1829455832_079af99f76_ff244d5af6.jpg]]></image:loc><image:title><![CDATA[Modalis Partners with SOLVE FSHD to Develop CRISPR Therapy for Facioscapulohumeral Muscular Dystrophy]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/solve-fshd-and-modalis-announce-strategic-collaboration-to-develop-an-innovative-crispr-based-epigen/]]></loc><lastmod>2025-06-09T12:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-6-june-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-06-06T12:39:39+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-2148124393_94e72790ab_a2ee2ee67b.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (6 June 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/oncolytic-virus-immunotherapy-strategic-research-business-report-2025-2030-surge-in-clinical-trials/]]></loc><lastmod>2025-06-05T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-cas9-screens-uncover-nr2f2-as-a-key-regulator-of-endocrine-resistance-in-breast-cancer/]]></loc><lastmod>2025-06-05T14:04:57+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1129129422_39d34a42be_00c38506b9.jpg]]></image:loc><image:title><![CDATA[CRISPR-Cas9 Screens Uncover NR2F2 as a Key Regulator of Endocrine Resistance in Breast Cancer]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/allogene-therapeutics-allo-316-shows-durable-responses-in-advanced-renal-cell-carcinoma/]]></loc><lastmod>2025-06-04T15:50:13+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-2167784408_721de620c1_5c0811415b.jpg]]></image:loc><image:title><![CDATA[Allogene Therapeutics' ALLO-316 Shows Durable Responses in Advanced Renal Cell Carcinoma]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/gene-editing-market-research-2025-2029-by-application-technology-place-industry-and-product-with/]]></loc><lastmod>2025-06-03T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/breaking-crispr-cas13-enables-programmable-rna-acetylation/]]></loc><lastmod>2025-06-02T14:28:18+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_xBrief0206_16195ef631_7d6ec3b2ec.jpg]]></image:loc><image:title><![CDATA[Breaking: CRISPR-CAS13 enables programmable RNA acetylation]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-30-may-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-05-30T12:41:37+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1533978848__1__45ca04b6eb_7627e1c430.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (30 May 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/capsida-receives-fda-fast-track-designation-for-its-potential-first-in-class-iv-administered-gene-th/]]></loc><lastmod>2025-05-29T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-mediated-removal-of-mutated-col7a1-exons-shows-therapeutic-potential-for-epidermolysis-bullos/]]></loc><lastmod>2025-05-29T16:44:52+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1436363837_d2715323d4_ff327d7c56.jpg]]></image:loc><image:title><![CDATA[CRISPR-Mediated Removal of Mutated COL7A1 Exons Shows Therapeutic Potential for Epidermolysis Bullosa]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/dia-2025-global-annual-meeting-spotlights-fda-leadership-with-opening-plenary-fda-town-hall-and-gl/]]></loc><lastmod>2025-05-28T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/genomic-cancer-panel-and-profiling-market-research-report-2025-2029-with-executive-amp-consultant/]]></loc><lastmod>2025-05-28T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/medable-introduces-long-term-follow-up-model-for-cell-amp-gene-therapy-cgt-trials-to-reduce-cost/]]></loc><lastmod>2025-05-28T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/base-editors-reshape-pathogenic-repeats/]]></loc><lastmod>2025-05-27T10:04:39+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief2705_eeda53fd25_47f5a908b6.jpg]]></image:loc><image:title><![CDATA[Base editors reshape pathogenic repeats]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/carbon-newsletter-27-may-2025-your-latest-news-about-crispr-in-agrobio/]]></loc><lastmod>2025-05-27T09:57:51+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Carbon2705_2de6868a3c_f068ee6c03.jpg]]></image:loc><image:title><![CDATA[CARBON Newsletter (27 May 2025) - Your Latest News About CRISPR in AgroBio]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-23-may-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-05-27T21:03:53+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML2305_0f7a61cabd_26df87fed3.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (23 May 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/navigating-the-cast-landscape-a-review-of-mechanisms-and-therapeutic-potential/]]></loc><lastmod>2025-05-22T17:01:25+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-815702424__1__241e4b5127_25652c524c.jpg]]></image:loc><image:title><![CDATA[Navigating the CAST Landscape: A Review of Mechanisms and Therapeutic Potential]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/scribe-therapeutics-reports-positive-preclinical-data-on-its-novel-crispr-technologies-at-the-2025-e/]]></loc><lastmod>2025-05-22T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/first-ever-prime-editing-therapy-shows-safety-and-efficacy-in-patient-with-chronic-granulomatous-dis/]]></loc><lastmod>2025-05-21T17:29:23+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-2187400559_04f8739293_3b90455777.jpg]]></image:loc><image:title><![CDATA[First-Ever Prime-Editing Therapy Shows Safety and Efficacy in Patient With Chronic Granulomatous Disease]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/2-day-molecular-biology-for-the-non-molecular-biologist-training-course-elevate-your-expertise-in-p/]]></loc><lastmod>2025-05-20T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/novel-adenine-base-editor-shows-superior-precision/]]></loc><lastmod>2025-05-20T12:55:39+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Monkey_85a1a42d10_94c0609e4b.jpg]]></image:loc><image:title><![CDATA[Novel adenine base editor shows superior precision]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/highlight-tripartite-complex-boosts-non-viral-gene-knock-in-accuracy/]]></loc><lastmod>2025-05-22T22:53:46+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_xBrief0519_f2adc604fc_d1eb644d1c.jpg]]></image:loc><image:title><![CDATA[Highlight: Tripartite complex boosts non-viral gene knock-in accuracy]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/be-biopharma-announces-new-preclinical-data-for-be-102-a-b-cell-medicine-for-the-potential-treatmen/]]></loc><lastmod>2025-05-17T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/acuitas-therapeutics-showcases-collaboration-with-childrens-hospital-of-philadelphia-for-personaliz/]]></loc><lastmod>2025-05-16T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-16-may-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-06-02T21:27:36+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1605_934da63254_9ec6634c2f.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (16 May 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/aldevron-and-integrated-dna-technologies-manufacture-worlds-first-mrna-based-personalized-crispr-th-1/]]></loc><lastmod>2025-05-16T12:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/aldevron-and-integrated-dna-technologies-manufacture-worlds-first-mrna-based-personalized-crispr-th/]]></loc><lastmod>2025-05-15T20:00:03+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/first-patient-treated-with-personalized-crispr-therapy-developed-in-just-six-months/]]></loc><lastmod>2025-05-15T20:00:03+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/breaking-first-personalised-mrna-crispr-therapy-delivered-in-six-months/]]></loc><lastmod>2025-05-20T10:00:46+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Breaking0515_f666d33096_8356d1aff1.jpg]]></image:loc><image:title><![CDATA[Breaking: First personalised mRNA CRISPR therapy delivered in six months]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/capsida-presents-new-glp-toxicology-data-supporting-recent-fda-ind-clearance-of-its-first-in-class/]]></loc><lastmod>2025-05-14T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/the-latest-clinical-trial-updates-from-crispr-medicine-news/]]></loc><lastmod>2025-05-20T23:48:11+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-687810706_54b75d15d5_3e0c25454c.jpg]]></image:loc><image:title><![CDATA[The Latest Clinical Trial Updates from CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/circular-ssdna-boosts-talen-editing-efficiency/]]></loc><lastmod>2025-05-13T10:58:39+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief1305_f225df9127_462d51ccb0.jpg]]></image:loc><image:title><![CDATA[Circular ssDNA boosts TALEN editing efficiency]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/modalis-has-been-selected-as-a-finalist-in-the-xprize-healthspan-fshd-bonus-prize-competition-and-aw/]]></loc><lastmod>2025-05-13T12:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/capsida-receives-fda-ind-clearance-for-its-first-in-class-iv-administered-gene-therapy-for-stxbp1-d/]]></loc><lastmod>2025-05-12T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/gene-editing-for-muscular-dystrophies-where-do-we-stand/]]></loc><lastmod>2025-07-21T11:48:57+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_headshot_Cecilia_Jimenez-Mallebrera__1__64d5a296b8_6a13e2c085.jpg]]></image:loc><image:title><![CDATA[Gene Editing for Muscular Dystrophies: Where Do We Stand?]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-9-may-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-05-09T11:44:36+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-2165327439_bda125cace_2218a4dd89.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (9 May 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/dia-2025-global-annual-meeting-spotlights-the-power-of-collaboration-amid-shifting-regulatory-priori/]]></loc><lastmod>2025-05-08T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/minimal-cas9-ancestor-enables-durable-epigenetic-control/]]></loc><lastmod>2025-05-08T09:55:56+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_20250508__NovaIscB_52e9f2b545_fe6f70dafb.jpg]]></image:loc><image:title><![CDATA[Minimal Cas9 ancestor enables durable epigenetic control]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/breaking-crispr-gene-activation-rescues-neuronal-defects-in-uba5-associated-encephalopathy/]]></loc><lastmod>2025-05-07T20:07:20+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1137402171-kopi_057acf876e_b456f42994.jpg]]></image:loc><image:title><![CDATA[Breaking: CRISPR Gene Activation Rescues Neuronal Defects in UBA5-Associated Encephalopathy]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/mission-bio-and-integrated-dna-technologies-partner-to-advance-single-cell-precision-in-crispr-genom/]]></loc><lastmod>2025-05-06T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/txnip-affects-stress-pathways-without-boosting-metabolic-cell-function/]]></loc><lastmod>2025-05-06T11:50:51+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_0605ER_87ed40f415_1ce23c5263.jpg]]></image:loc><image:title><![CDATA[TXNIP affects stress pathways without boosting metabolic cell function]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/vertex-reports-first-quarter-2025-financial-results/]]></loc><lastmod>2025-05-06T12:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/scribe-therapeutics-to-highlight-in-vivo-crispr-based-genome-editing-data-for-duchenne-muscular-dyst/]]></loc><lastmod>2025-05-05T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/epicrispr-biotechnologies-announces-five-presentations-highlighting-advances-in-epigenetic-modulatio/]]></loc><lastmod>2025-05-05T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/highlight-crispr-screen-identifies-sfrp1-as-key-regulator-of-skin-cell-proliferation/]]></loc><lastmod>2025-05-06T11:52:31+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Extende0505_88c810d5fc_450a7786a7.jpg]]></image:loc><image:title><![CDATA[Highlight: CRISPR Screen Identifies SFRP1 as Key Regulator of Skin Cell Proliferation]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-2-may-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-05-05T23:01:19+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML0205_c6dab0ffb2_39d495690b.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (2 May 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/mammoth-biosciences-to-present-preclinical-data-on-in-vivo-gene-editing-of-skeletal-muscle-in-non-hu/]]></loc><lastmod>2025-05-01T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/repare-therapeutics-announces-out-licensing-of-its-discovery-platforms-to-dcx-biotherapeutics/]]></loc><lastmod>2025-05-01T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/machine-learning-unlocks-custom-crispr-enzymes-for-precision-editing/]]></loc><lastmod>2025-05-07T13:42:15+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_download__3__f9d311aa05_41dee3cf9a.jpg]]></image:loc><image:title><![CDATA[Machine Learning Unlocks Custom CRISPR Enzymes for Precision Editing]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/carbon-newsletter-29-april-2025-your-latest-news-about-crispr-in-agrobio/]]></loc><lastmod>2025-04-29T15:04:06+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CARBON2904_d851f5eaba_da8a449281.jpg]]></image:loc><image:title><![CDATA[CARBON Newsletter (29 April 2025) - Your Latest News About CRISPR in AgroBio]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/nav17-mutation-causes-hyperexcitable-patient-derived-neurons/]]></loc><lastmod>2025-05-06T11:08:10+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Ondtifoden_6d421b7044_d181d55483.jpg]]></image:loc><image:title><![CDATA[Nav1.7 mutation causes hyperexcitable patient-derived neurons]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/be-biopharma-to-present-at-the-american-society-of-gene-and-cell-therapy-asgct-28th-annual-meeting/]]></loc><lastmod>2025-04-29T12:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/capsida-to-present-progress-updates-at-the-asgct-annual-meeting-including-nhp-glp-toxicology-study/]]></loc><lastmod>2025-04-29T12:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/genetic-testing-market-size-and-share-analysis-growth-trends-and-forecast-report-2025-2033-resear/]]></loc><lastmod>2025-04-28T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/scribe-achieves-milestone-for-in-vivo-program-in-collaboration-with-prevail-therapeutics-a-part-of/]]></loc><lastmod>2025-04-28T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/tempus-introduces-loop-an-ai-powered-target-discovery-and-validation-platform/]]></loc><lastmod>2025-04-28T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/an-innovative-approach-to-treating-cystic-fibrosis-using-base-editors/]]></loc><lastmod>2025-04-28T16:25:38+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_headshot_CF_930f8dd8fa_9463032d46.jpg]]></image:loc><image:title><![CDATA[An Innovative Approach to Treating Cystic Fibrosis Using Base Editors]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/repare-therapeutics-announces-six-abstracts-accepted-for-presentation-at-aacr-annual-meeting-2025/]]></loc><lastmod>2025-04-25T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-25-april-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-04-25T16:34:17+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1644946153_c1fe86254a_78897cd90a.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (25 April 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/oral-trap1-targeting-crispr-therapy-boosts-colorectal-cancer-treatment-in-multiple-disease-models/]]></loc><lastmod>2025-04-24T15:16:22+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1964976457_331537a69c_25af23b8aa.jpg]]></image:loc><image:title><![CDATA[Oral TRAP1-Targeting CRISPR Therapy Boosts Colorectal Cancer Treatment in Multiple Disease Models]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/scribe-therapeutics-to-unveil-latest-preclinical-data-on-proprietary-crispr-epigenetic-silencing-tec/]]></loc><lastmod>2025-04-23T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/editco-bio-and-promega-partner-to-power-a-new-era-of-biologically-relevant-cell-based-research/]]></loc><lastmod>2025-04-22T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crisprmed25-poster-prize-winners-highlight-diverse-advances-in-crispr-medicine/]]></loc><lastmod>2025-04-22T13:57:11+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-687810462_3c5e7771ef_cbbe9f2885.jpg]]></image:loc><image:title><![CDATA[CRISPRMED25 Poster Prize Winners Highlight Diverse Advances in CRISPR Medicine]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/advanced-therapy-medicinal-products-global-strategic-business-report-2025-with-profiles-of-bluebird/]]></loc><lastmod>2025-04-21T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/celfi-assay-tracks-indels-to-validate-crispr-knockout-screens/]]></loc><lastmod>2025-04-21T16:48:17+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ExtendedBrief2104_f4c94a1f74_b503e13fb1.jpg]]></image:loc><image:title><![CDATA[CelFi Assay Tracks Indels to Validate CRISPR Knockout Screens]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/wrapping-up-crisprmed25-and-gearing-up-for-crisprmed26/]]></loc><lastmod>2025-04-19T08:19:52+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_PHOTO-2025-04-11-16-23-52__1__6a1bb57fa8_2bd365d470.jpg]]></image:loc><image:title><![CDATA[Wrapping up CRISPRMED25, and Gearing up for CRISPRMED26]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/enplusone-biosciences-appoints-clare-murray-phd-as-ceo/]]></loc><lastmod>2025-04-17T20:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/light-activated-crrnas-enable-controlled-crispr-editing/]]></loc><lastmod>2025-04-17T09:51:14+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief1704_f757de4e39_0a95d61d66.jpg]]></image:loc><image:title><![CDATA[Light-activated crRNAs enable controlled CRISPR editing]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/gene-editing-boosts-immunotherapy/]]></loc><lastmod>2025-04-15T11:48:08+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief1504_55fde343ec_7240720aff.jpg]]></image:loc><image:title><![CDATA[Gene editing boosts immunotherapy]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/quantum-enhanced-crispr-based-epigenome-editing-crispr-medicine-2025-conference-poster-highlight/]]></loc><lastmod>2025-04-16T22:36:39+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_QUANTUM_bb43c166d8_a1e384e22c.jpg]]></image:loc><image:title><![CDATA[Quantum-Enhanced CRISPR-Based Epigenome Editing: CRISPR Medicine 2025 Conference Poster Highlight]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/quantum-guided-gene-editing-in-a-life-saving-bone-marrow-transplant-a-highlight-from-crisprmed25/]]></loc><lastmod>2025-04-16T22:35:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Nyhavn_in_copenhagen_harbour_c17515073f_7b2e132191.jpg]]></image:loc><image:title><![CDATA[Quantum-Guided Gene Editing in a Life-Saving Bone Marrow Transplant: A Highlight from CRISPRMED25]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-11-april-2025-crisprmed25-special/]]></loc><lastmod>2025-04-15T08:26:53+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Collage_774c856283_7af8308ff6.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (11 April 2025) - CRISPRMED25 Special]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crisprmed25-launches-with-afternoon-virtual-session-to-be-followed-by-four-days-of-in-person-session/]]></loc><lastmod>2025-04-16T22:31:28+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-2064008759_ee7cd3c83c_aebc3116d7.jpg]]></image:loc><image:title><![CDATA[CRISPRMED25 Launches with Afternoon Virtual Session to Be Followed by Four Days of In-Person Sessions]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/second-part-of-crisprmed25-opening-day-features-virtual-poster-sessions-next-four-days-will-be-in-p/]]></loc><lastmod>2025-04-16T22:35:19+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1887025459_2beb025be4_e211259536.jpg]]></image:loc><image:title><![CDATA[Second Part of CRISPRMED25 Opening Day Features Virtual Poster Sessions; Next Four Days Will Be In-Person Sessions]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/cellares-and-university-of-wisconsin-school-of-medicine-and-public-health-to-automate-clinical-scale/]]></loc><lastmod>2025-04-10T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crisprmed25-virtual-event-roundup/]]></loc><lastmod>2025-04-18T16:16:20+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-815702424_a41d36c3a0_7773407d1b.jpg]]></image:loc><image:title><![CDATA[CRISPRMED25 Virtual Event Roundup]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/colossal-announces-worlds-first-de-extinction-birth-of-dire-wolves/]]></loc><lastmod>2025-04-07T20:00:02+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-enhancer-increases-precision-and-destroys-dna/]]></loc><lastmod>2025-04-07T11:34:46+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_HeadshotAZD7648_6153cd86a3_638f1b6875.jpg]]></image:loc><image:title><![CDATA[CRISPR Enhancer Increases Precision – and Destroys DNA]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-4-april-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-04-04T21:14:26+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML0404_341347cdc4_bdf4387849.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (4 April 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/we-row-for-william-157-miles-one-nonstop-journey-of-hope/]]></loc><lastmod>2025-04-04T12:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/parse-biosciences-partners-with-japanese-distributor-scrum-inc/]]></loc><lastmod>2025-04-03T12:00:01+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-arms-hspcs-to-resist-and-fight-hiv-1/]]></loc><lastmod>2025-04-01T11:31:37+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief0104_a989803be8_11fa1644f8.jpg]]></image:loc><image:title><![CDATA[CRISPR arms HSPCs to resist and fight HIV-1]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/crispr-cas9-market-research-report-2024-positioned-for-exponential-growth-with-advancements-in-gene/]]></loc><lastmod>2025-03-28T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-28-march-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-03-28T16:55:25+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1166875916_896d921283_d03445c487.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (28 March 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/lantern-pharma-provides-business-updates-and-fourth-quarter-amp-year-end-2024-financial-results/]]></loc><lastmod>2025-03-28T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/precision-biosciences-reports-fourth-quarter-and-fiscal-year-2024-financial-results-and-provides-bus/]]></loc><lastmod>2025-03-26T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/carbon-newsletter-26-march-2025-your-latest-news-about-crispr-in-agrobio/]]></loc><lastmod>2025-03-26T14:55:23+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Carbon2603_523c948894_3ccf3e1836.jpg]]></image:loc><image:title><![CDATA[CARBON Newsletter (26 March 2025) - Your Latest News About CRISPR in AgroBio]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/united-states-molecular-diagnostics-market-forecast-report-and-company-analysis-2025-2033-featuring/]]></loc><lastmod>2025-03-25T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-screen-uncovers-arl11-as-key-determinant-in-parp-inhibitor-resistance/]]></loc><lastmod>2025-03-24T13:28:14+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Highlight2403_38800708a9_b7a1e92dc5.jpg]]></image:loc><image:title><![CDATA[CRISPR Screen Uncovers ARL11 as Key Determinant in PARP Inhibitor Resistance]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-21-march-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-03-21T15:02:57+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML2103_f87fbdf73f_6b4894575e.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (21 March 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/parse-biosciences-expands-global-reach-with-the-south-australian-genomics-centre-as-certified-servic/]]></loc><lastmod>2025-03-21T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/fda-clears-first-ever-in-vivo-gene-editing-trial-for-chronic-hepatitis-b-in-the-united-states/]]></loc><lastmod>2025-05-20T10:10:26+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1465361950_f4788e9ddd_6b93842ca2.jpg]]></image:loc><image:title><![CDATA[FDA Clears First-Ever In Vivo Gene-Editing Trial for Chronic Hepatitis B in the United States]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-targets-key-cancer-gene-in-ewing-sarcoma/]]></loc><lastmod>2025-03-18T12:26:24+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief1803_7283471403_e22f9a55d1.jpg]]></image:loc><image:title><![CDATA[CRISPR targets key cancer gene in Ewing sarcoma]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/single-dose-therapeutic-genome-editing-using-lipid-nanoparticles-shows-promise-in-mouse-models-of-ra/]]></loc><lastmod>2025-05-22T22:58:57+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_image__1__88043fd6c6_ae197543e8.png]]></image:loc><image:title><![CDATA[Single-Dose Therapeutic Genome Editing Using Lipid Nanoparticles Shows Promise in Mouse Models of Rare Metabolic Disease]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-14-march-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-03-14T17:01:06+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-172994677_eb4d5a54f5_e0cd062168.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (14 March 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/beam-therapeutics-reports-clinical-proof-of-concept-data-for-beam-302-in-alpha-1-antitrypsin-deficie/]]></loc><lastmod>2025-03-19T16:56:26+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1560062778_aa074caccb_ea186b46ed.jpg]]></image:loc><image:title><![CDATA[Beam Therapeutics Reports Clinical Proof-Of-Concept Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Trial]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/roslinct-and-ayrmid-pharma-ltd-announce-their-intent-to-enter-into-a-strategic-partnership-to-manuf/]]></loc><lastmod>2025-03-11T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/hydrogel-delivery-system-shows-promise-for-cell-based-muscular-dystrophy-treatment/]]></loc><lastmod>2025-03-24T12:15:22+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1048716704_802ea6cca3_639d592cc9.jpg]]></image:loc><image:title><![CDATA[Hydrogel Delivery System Shows Promise for Cell-Based Muscular Dystrophy Treatment]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-editing-links-an-fto-variant-to-muscle-insulin-resistance/]]></loc><lastmod>2025-03-10T08:03:42+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Extended1003_48247086f1_d0df2a5435.jpg]]></image:loc><image:title><![CDATA[CRISPR editing links an FTO variant to muscle insulin resistance]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/repare-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/]]></loc><lastmod>2025-03-08T12:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/scribe-therapeutics-presents-data-on-its-epigenetic-long-term-x-repressor-technology-at-the-2025-key/]]></loc><lastmod>2025-03-07T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-7-march-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-03-07T17:14:05+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML0703_d94fe5a46b_b3c3684290.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (7 March 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/parse-biosciences-advances-plans-to-release-single-cell-chromatin-accessibility-products/]]></loc><lastmod>2025-03-04T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/colossal-creates-the-colossal-woolly-mouse-showcasing-breakthroughs-in-multiplex-genome-editing-and/]]></loc><lastmod>2025-03-04T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/expanding-cas9-enhances-precision-in-base-editing/]]></loc><lastmod>2025-03-04T13:19:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief0403_aa1d8aee0c_d696d751c1.jpg]]></image:loc><image:title><![CDATA[Expanding Cas9 Enhances Precision in Base Editing]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/repare-therapeutics-provides-business-and-clinical-update-and-reports-fourth-quarter-and-full-year-2/]]></loc><lastmod>2025-03-03T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-28-february-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-02-28T16:15:28+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1043992236_4071ecead6_30cc4c482b.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (28 February 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/company/card/papillon-therapeutics/]]></loc><lastmod>2025-02-26T22:41:44+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/company/card/epitor-therapeutics/]]></loc><lastmod>2025-02-26T22:36:36+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/company/card/navega-therapeutics/]]></loc><lastmod>2025-02-26T22:33:05+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/company/card/peterbio/]]></loc><lastmod>2025-02-26T22:12:34+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/scribe-therapeutics-to-participate-in-upcoming-conferences-1/]]></loc><lastmod>2025-02-26T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/the-latest-updates-from-the-gene-editing-clinical-trials-february-2025/]]></loc><lastmod>2025-03-12T13:16:57+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1063070548_02e0b535ef_d1976783f2.jpg]]></image:loc><image:title><![CDATA[The Latest Updates From the Gene-Editing Clinical Trials (February 2025)]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/castration-resistant-prostate-cancer-crpc-and-salivary-gland-cancer-sgc-nct04249947/]]></loc><lastmod>2025-05-20T09:35:06+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/carbon-newsletter-25-february-2025-your-latest-news-about-crispr-in-agrobio/]]></loc><lastmod>2025-02-25T14:47:51+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CARBON2502_6c387bfd45_9b828667ef.jpg]]></image:loc><image:title><![CDATA[CARBON Newsletter (25 February 2025) - Your Latest News About CRISPR in AgroBio]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/rna-based-therapies-for-metabolic-liver-diseases/]]></loc><lastmod>2025-02-25T13:55:19+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1178017792_ea8183dea3_8b38a859f6.jpg]]></image:loc><image:title><![CDATA[RNA-based Therapies for Metabolic Liver Diseases]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/airna-harnessing-the-bodys-rna-editing-system-for-therapeutic-applications/]]></loc><lastmod>2025-02-27T20:33:32+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Kris_and_Thorsten_merge_c2d29bd22d_90cd2b0654.jpg]]></image:loc><image:title><![CDATA[AIRNA: Harnessing the Body’s RNA-Editing System for Therapeutic Applications]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-21-february-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-02-21T15:25:42+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML2102_5efaaa6a0c_ce14418a59.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (21 February 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/bahrain-reports-first-administration-of-casgevy-in-the-middle-east/]]></loc><lastmod>2025-02-19T09:48:11+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1333139316_5ea55a895b_6a8057c520.jpg]]></image:loc><image:title><![CDATA[Bahrain Reports First Administration of CASGEVY in the Middle East]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/parse-biosciences-launches-5-million-cell-evercode-wt-penta-kit-for-single-cell-sequencing/]]></loc><lastmod>2025-02-19T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-csm-enables-single-molecule-rna-imaging-in-cells/]]></loc><lastmod>2025-02-18T13:34:10+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief1802_6d7a83912e_5058e41dcb.jpg]]></image:loc><image:title><![CDATA[CRISPR–Csm enables single-molecule RNA imaging in cells]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/cellistic-launches-allo-chassistm-ready-to-use-immune-cloaked-ipsc-cell-lines-facilitating-cost-eff/]]></loc><lastmod>2025-02-17T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-screen-links-baf-mutation-to-premature-ageing/]]></loc><lastmod>2025-02-17T13:44:11+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brie1702_ad1475d481_0cf722cc1e.jpg]]></image:loc><image:title><![CDATA[CRISPR screen links BAF mutation to premature ageing]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-14-february-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-02-14T14:27:46+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-2160062160_d2a1c558b2_400fc4812b.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (14 February 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/company/card/nephrogen-biotech/]]></loc><lastmod>2025-02-13T11:22:05+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/fda-grants-dual-designations-to-arbors-gene-editing-therapy-for-rare-kidney-disease/]]></loc><lastmod>2025-12-30T23:15:04+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1453826272_9037d64205_a17287bb94.jpg]]></image:loc><image:title><![CDATA[FDA Grants Dual Designations to Arbor's Gene Editing Therapy for Rare Kidney Disease]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/vertex-reports-fourth-quarter-and-full-year-2024-financial-results/]]></loc><lastmod>2025-02-11T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/metastatic-melanoma-nct06783270-2/]]></loc><lastmod>2026-02-26T12:12:28+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/metastatic-melanoma-nct06783270/]]></loc><lastmod>2025-06-17T23:04:28+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/company/card/lyell-immunopharma/]]></loc><lastmod>2025-02-07T23:10:57+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-7-february-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-02-07T11:52:44+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML0702_eec8ed103e_f0e570189d.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (7 February 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/broken-string-biosciences-launches-catalyst-program-to-shorten-gene-editing-therapy-development-by-m/]]></loc><lastmod>2025-02-06T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/cd70-targeting-therapies-clinical-trials-amp-market-opportunity-insight-2025-cusatuzumab-emerges/]]></loc><lastmod>2025-02-05T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/parse-biosciences-invalidates-all-10x-genomics-patent-claims-asserted-against-its-products/]]></loc><lastmod>2025-02-04T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/focused-ultrasound-enhances-crispr-delivery-to-the-brain/]]></loc><lastmod>2025-02-04T12:24:32+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Brief0402_4f1db3d4f6_a69a673091.jpg]]></image:loc><image:title><![CDATA[Focused ultrasound enhances CRISPR delivery to the brain]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crisprmed25-interview-avencia-sanchez-mejias-integra-therapeutics/]]></loc><lastmod>2025-02-03T16:05:42+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Avencia_S_INTEGRA_bdae0e1825_5cac05dae6.jpg]]></image:loc><image:title><![CDATA[CRISPRMED25 - Interview: Avencia Sánchez-Mejías (Integra Therapeutics)]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-next-frontier-in-vivo-editing-of-the-microbiome-interview-with-xavier-duportet-eligo-biosc/]]></loc><lastmod>2025-02-03T14:58:27+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Xavier_Duportet_Eligo_1bb4633ef3_675704fb4d.jpg]]></image:loc><image:title><![CDATA[CRISPR Next Frontier: In Vivo Editing of the Microbiome. Interview With Xavier Duportet, Eligo Bioscience]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/mammoth-biosciences-announces-new-results-on-nanocas-the-first-efficient-ultracompact-extrahepatic/]]></loc><lastmod>2025-01-31T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-31-january-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-01-31T08:32:03+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-2038347417_41a06699b3_080d4a4236.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (31 January 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/vertex-announces-casgevyr-reimbursement-agreement-for-the-treatment-of-sickle-cell-disease-in-englan/]]></loc><lastmod>2025-01-31T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/gene-delivery-systems-market-research-2024-what-drives-the-growth-and-demand-for-gene-therapy-solut/]]></loc><lastmod>2025-01-30T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/job/postdoctoral-and-graduate-fellow-positions/]]></loc><lastmod>2025-01-30T11:08:56+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_36baa52558e53bc5b7ff104a398a188c-Logo-A-Positivo-Colore_df76e908b8_916eb9ae2c.png]]></image:loc><image:title><![CDATA[Postdoctoral and graduate fellow positions]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/allogenes-dual-acting-car-t-candidate-allo-329-gets-fda-green-light-for-autoimmune-disease-trial/]]></loc><lastmod>2025-01-29T22:30:33+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1393824880_47489cc300_10dfefa14f.jpg]]></image:loc><image:title><![CDATA[Allogene's Dual-Acting CAR T Candidate ALLO-329 Gets FDA Green Light for Autoimmune Disease Trial]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/maravai-lifesciences-acquires-assets-and-intellectual-property-from-molecular-assemblies/]]></loc><lastmod>2025-01-29T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/editco-bio-inc-launches-xdel-knockout-cells-redefining-crispr-gene-editing-efficiency-and-reprodu/]]></loc><lastmod>2025-01-28T20:00:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/carbon-newsletter-28-january-2025-your-latest-news-about-crispr-in-agrobio/]]></loc><lastmod>2025-01-28T16:44:47+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CARBON2801_a82b4dc486_e98c1131da.jpg]]></image:loc><image:title><![CDATA[CARBON Newsletter (28 January 2025) - Your Latest News About CRISPR in AgroBio]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/new-triple-action-crispr-technology-enables-simultaneous-gene-activation-repression-and-deletion-i/]]></loc><lastmod>2025-02-07T10:23:56+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Picture_authors_news_Article_c6b2b1c03f_e2db6c7045.jpg]]></image:loc><image:title><![CDATA[New Triple-Action CRISPR Technology Enables Simultaneous Gene Activation, Repression, and Deletion in Primary Human T Cells]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/company/card/grit-biotechnology/]]></loc><lastmod>2025-01-25T17:37:52+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/company/card/helex-bio/]]></loc><lastmod>2025-01-25T17:31:39+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/company/card/kaedi-bio/]]></loc><lastmod>2025-01-25T17:26:33+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/company/card/gentibio/]]></loc><lastmod>2025-01-25T17:21:36+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/company/card/algenscribe-therapeutics/]]></loc><lastmod>2025-01-25T17:08:54+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-24-january-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-02-06T20:28:33+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML2401_e06dbda544_7a13e4df06.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (24 January 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/company/card/korro-bio/]]></loc><lastmod>2025-01-23T00:02:09+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-enables-complete-control-of-neuronal-lrrtm2/]]></loc><lastmod>2025-01-21T12:44:12+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_20250121__Synapse-kopi_abbd532f4b_507564037d.jpg]]></image:loc><image:title><![CDATA[CRISPR enables complete control of neuronal LRRTM2]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crisprmed24-testimonial-laura-castilla-vallmanya-phd/]]></loc><lastmod>2025-01-21T11:49:08+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-2100850584_3b721a63eb_2846b18d47.jpg]]></image:loc><image:title><![CDATA[CRISPRMED24 Testimonial - Laura Castilla-Vallmanya, Ph.D]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/review-explores-crispr-delivery-methods-in-therapy/]]></loc><lastmod>2025-01-20T14:50:45+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_20250120__Delivery-kopi_7499cc0047_973110bdd4.jpg]]></image:loc><image:title><![CDATA[Review Explores CRISPR Delivery Methods in Therapy]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-17-january-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-01-17T13:35:07+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1305820206_c107f0d12b_af30a56db9.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (17 January 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/colossal-secures-200m-in-series-c-funding-from-twg-global-on-the-back-of-numerous-worlds-first-sci/]]></loc><lastmod>2025-01-15T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crispr-medicine-in-2024-a-recap/]]></loc><lastmod>2025-01-15T23:12:30+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_SoftRoundup2025__0306775dca_97a20f8a14.jpg]]></image:loc><image:title><![CDATA[CRISPR Medicine in 2024 - A Recap]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/crisprcasrx-mediated-silencing-of-htt-shows-therapeutic-potential-in-huntingtons-disease-models/]]></loc><lastmod>2025-01-15T23:09:56+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1533978848_e089399170_830b84e794.jpg]]></image:loc><image:title><![CDATA[CRISPR/CasRx-Mediated Silencing of HTT Shows Therapeutic Potential in Huntington’s Disease Models]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/disease/card/haemophilia-b-hereditary-factor-ix-deficiency/]]></loc><lastmod>2025-01-13T21:02:02+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/disease/card/amyotrophic-lateral-sclerosis-als/]]></loc><lastmod>2025-01-13T20:49:25+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/dna-sequencing-research-applied-and-clinical-markets-report-2025-rapid-advances-in-ngs-and-tgs-pr/]]></loc><lastmod>2025-01-13T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/scribe-therapeutics-achieves-milestone-for-in-vivo-program-in-collaboration-with-sanofi/]]></loc><lastmod>2025-01-13T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/integrated-dna-technologies-names-ajay-gannerkote-as-new-president-to-lead-bold-era-of-innovation-an/]]></loc><lastmod>2025-01-13T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/systemic-lupus-erythematosus-sle-nct06752876/]]></loc><lastmod>2025-06-02T22:39:45+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/systemic-lupus-erythematosus-sle-nct06752876-2/]]></loc><lastmod>2026-03-04T13:36:01+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/clinical-trial/chronic-hepatitis-b-hbv-nct06671093/]]></loc><lastmod>2025-05-20T09:35:06+02:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/new-clinical-trial/chronic-hepatitis-b-hbv-nct06671093-2/]]></loc><lastmod>2026-02-26T12:09:53+01:00</lastmod><changefreq>monthly</changefreq><priority>0.7</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/cmn-weekly-10-january-2025-your-weekly-crispr-medicine-news/]]></loc><lastmod>2025-01-10T15:16:38+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_ML1001_f0bdeb7c4a_7fd0768cf5.jpg]]></image:loc><image:title><![CDATA[CMN Weekly (10 January 2025) - Your Weekly CRISPR Medicine News]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/repare-therapeutics-announces-portfolio-re-prioritization-partnering-initiatives-and-cost-reduction/]]></loc><lastmod>2025-01-10T12:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/oligonucleotide-synthesis-market-research-report-2025-with-executive-and-consultant-guides-amp-pr/]]></loc><lastmod>2025-01-09T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/scribe-therapeutics-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference/]]></loc><lastmod>2025-01-09T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/ambry-genetics-data-supports-functional-study-of-brca2-helping-improve-variant-classification-for-h/]]></loc><lastmod>2025-01-08T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/mammoth-biosciences-to-present-at-43rd-annual-jp-morgan-healthcare-conference/]]></loc><lastmod>2025-01-08T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/whole-genome-and-exome-sequencing-market-research-2025-with-executive-and-consultant-guides-amp-p/]]></loc><lastmod>2025-01-08T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/corrixr-therapeutics-appoints-jan-case-as-chief-operating-officer/]]></loc><lastmod>2025-01-08T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url><url><loc><![CDATA[https://crisprmedicinenews.com/job/computational-scientist-for-optical-pooled-screening-infrastructure/]]></loc><lastmod>2025-01-08T14:52:17+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_8585084d7ed92c06ad374123b4513490-Den-velkendte-sljfe_0723111582_23dee6029a.jpg]]></image:loc><image:title><![CDATA[Computational scientist for optical pooled screening infrastructure]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/news/tune-therapeutics-hbv-epigenetic-silencer-clinical-trial-programme-expands-to-hong-kong/]]></loc><lastmod>2025-01-08T14:20:37+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority><image:image><image:loc><![CDATA[https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_iStock-1439770412_aea2e177fe_d8b7119f67.jpg]]></image:loc><image:title><![CDATA[Tune Therapeutics' HBV Epigenetic Silencer: Clinical Trial Programme Expands to Hong Kong]]></image:title></image:image></url><url><loc><![CDATA[https://crisprmedicinenews.com/press-release-service/card/profluent-demonstrates-ai-can-engineer-protein-dna-interactions-without-iterative-laboratory-screeni/]]></loc><lastmod>2025-01-07T20:00:01+01:00</lastmod><changefreq>yearly</changefreq><priority>0.6</priority></url></urlset>